Educational
Dr. Sandy Adel
April 15, 2026 · 15 min read
Plastic surgery marketing in the United States is not a free-for-all. It never has been. The FTC has always required that advertising claims be truthful and substantiated. The FDA controls what you can say about the devices and treatments you use. And your State Medical Board has its own set of rules about how you represent your qualifications and scope of practice.
What has changed in recent years is enforcement. The FTC updated its Endorsement Guides in 2023. The FDA has increased its oversight of direct-to-consumer promotion. State boards have become more active on social media. And patients, armed with more information than ever, are more likely to report misleading advertising when they see it.
This guide explains what the FTC, FDA, and State Medical Boards require of plastic surgeons when marketing their practices, in plain language, with concrete examples so you can see exactly where the line is. If you want marketing that is built compliance-first from the first draft, visit theContentClicks Plastic and Cosmetic Surgery page to learn how the process works for practices across the US.
Three regulatory bodies share jurisdiction over plastic surgery advertising in the United States, each covering different aspects of your marketing. Compliance with one does not guarantee compliance with the others.
The Federal Trade Commission (FTC) has primary responsibility for all forms of advertising. Its fundamental requirement is that every advertising claim must be truthful, non-deceptive, and substantiated by competent and reliable scientific evidence before it is made, as outlined in the FTC Health Products Guidance. This applies to your website, your social media, your paid ads, and any content a marketing agency produces on your behalf. The FTC does not pre-approve advertising. The burden to substantiate every claim sits with you before anything is published.
The Food and Drug Administration (FDA) has primary responsibility for the labelling and promotion of FDA-regulated products, including medical devices used in surgical procedures and prescription medicines. When you advertise specific treatments, technologies, or injectables, FDA advertising rules apply alongside FTC standards. The two agencies coordinate their enforcement through a formal memorandum of understanding known as the FDA-FTC Liaison Agreement.
State Medical Boards regulate professional conduct at the state level, including how practitioners represent their qualifications, titles, and scope of practice in advertising. Rules vary by state, and practitioners must comply with the regulations of every state in which they are licensed. Compliance with federal standards does not guarantee compliance with state-level requirements. The American Society of Plastic Surgeons also publishes ethical advertising guidance that members are expected to follow.
The FTC’s core requirement sounds simple, but applying it to plastic surgery advertising is more nuanced than it first appears. Every claim must be truthful, not deceptive, and backed by evidence. What this looks like in practice depends on the specific content you are producing.
A claim is considered deceptive if it is likely to mislead a reasonable consumer in a way that materially affects their decision to seek a service. The FTC evaluates the overall impression of an advertisement, not just the literal meaning of individual words. This means that even technically accurate statements can be deceptive if the broader impression they create is misleading.
The following are non-compliant under FTC standards: guaranteed outcomes such as “guaranteed results,” “permanent solution,” “painless procedure,” “zero risk” or “completely safe”; unsubstantiated superiority claims such as “the best plastic surgeon in [city]” or “America’s top-rated practice”; claims that cannot be substantiated by clinical evidence; misleading before-and-after imagery that does not represent typical patient outcomes; and testimonials that describe results without any disclosure of whether those results are typical.
US advertising law does permit puffery, which refers to boastful statements so vague or exaggerated that no reasonable consumer would interpret them as factual claims. Statements like “a practice dedicated to excellence” or “we love what we do” generally fall into this category. However, any statement that could be read as making a verifiable claim about outcomes, qualifications, or quality should be approached with care.
Testimonials are permitted in the US, but the FTC’s updated Endorsement Guides revised in 2023 impose specific requirements that many practices are not yet meeting.
Where a testimonial describes a specific outcome, the advertisement must make clear whether that outcome is typical for patients who undergo the procedure. If the outcome is not typical, a clear and conspicuous disclosure is required, for example: “Results are not typical. Individual outcomes vary based on a range of clinical and personal factors.”
If a patient, influencer, or other endorser received anything of value in exchange for their endorsement, including free treatment, a discount, or any form of compensation, that relationship must be clearly and conspicuously disclosed. Burying a disclosure in hashtags or fine print does not satisfy this requirement.
The FTC prohibits fabricated or misleading testimonials. Every endorsement must represent the honest, actual experience of the person providing it. Fabricated reviews, paid reviews presented as independent, and composite testimonials that misrepresent individual experiences are all prohibited.
When your advertising references specific FDA-regulated products, whether medical devices, FDA-cleared technologies, or prescription medicines, FDA rules apply in addition to the FTC standard.
Medical devices and prescription medicines may only be promoted for uses that have received FDA clearance or approval. Promoting a device or treatment for an off-label use, regardless of how common that use may be in clinical practice, is prohibited in advertising.
“FDA approved” and “FDA cleared” mean different things and must be used accurately. A device cleared through the FDA’s 510(k) pathway has not received full FDA approval. Using the phrase “FDA approved” for a 510(k)-cleared device is considered misleading by both agencies. The accurate term is “FDA cleared.” You can review the requirements in detail in the FDA’s device labelling guidance.
“FDA approved” and “FDA cleared” mean different things and must be used accurately. A device cleared through the FDA’s 510(k) pathway has not received full FDA approval. Using the phrase “FDA approved” for a 510(k)-cleared device is considered misleading by both agencies. The accurate term is “FDA cleared.” You can review the requirements in detail in the FDA’s device labelling guidance.
Social media is where most plastic surgery practices in the US face their greatest compliance exposure. The platforms move fast, the content is public and searchable, and the FTC’s 2023 updates specifically tightened the rules on influencer marketing and endorsements.
FTC rules apply on every platform without exception. Endorsement disclosures must appear where consumers are likely to see them, at the beginning of the caption and before the fold, not buried in a string of hashtags. Before-and-after images taken under materially different conditions presented as representative outcomes are misleading under FTC standards. State Medical Board rules also apply on social media, and many boards have specific guidance on how procedures can be described publicly. The American Society of Plastic Surgeons publishes ethical advertising guidance that is a useful reference alongside your state board’s requirements.
State Medical Boards regulate how licensed physicians represent themselves and their services in advertising. While the FTC and FDA set federal standards, state boards set their own requirements that apply independently and simultaneously.
Common areas of state-level regulation include the use of specialty designations and board certification titles in advertising, claims about training, qualifications, and areas of practice, the use of the word “specialist” and related terms, advertising procedures outside your licensed scope of practice, and rules on patient solicitation and commercial relationships. Practitioners must review the advertising guidance issued by the medical board in each state where they are licensed and update their approach whenever those guidelines change.
The consequences of non-compliant advertising in the US span financial penalties, professional sanctions, and civil litigation risk.
FTC enforcement can result in civil penalties, cease-and-desist orders, mandatory corrective advertising, and injunctions. FDA violations can result in warning letters, injunctions, consent decrees, and civil money penalties. State Medical Board enforcement can result in formal reprimand, conditions placed on your license, suspension from practice, or full revocation of your medical licence. Patients who suffer harm as a result of misleading advertising may also pursue civil claims, and class action litigation in the healthcare advertising space is not uncommon in the US.
Staying compliant in the US market requires attention to all three regulatory layers simultaneously.
Substantiate every claim before you publish it. If you cannot point to competent and reliable scientific evidence, do not make the claim. Update your testimonial disclosures to reflect the FTC’s 2023 requirements, including clear disclosure of material connections and whether outcomes described are typical. Check device and treatment claims against FDA-cleared labelling and remove any use of “FDA approved” language for 510(k)-cleared products. Review the advertising guidelines published by the medical board in every state where you hold a license, and revisit them regularly.
If your current marketing was not built with all three regulatory layers in mind, a review is worth doing before your next campaign goes live. Talk to the ContentClicks team about compliance-first marketing for plastic and cosmetic surgery practices in the US.
Plastic surgery advertising in the US is governed by three regulatory layers. The FTC requires that all advertising claims be truthful, non-deceptive, and substantiated by competent and reliable scientific evidence. The FDA regulates the promotion of specific medical devices, prescription medicines, and FDA-regulated treatments. State Medical Boards regulate professional conduct, titles, and qualifications in advertising at the state level.
Yes, but with significant compliance requirements. The FTC's 2023 Endorsement Guides require that testimonials reflect the genuine experience of the endorser, that any material connection between the endorser and the practice be clearly and conspicuously disclosed, and that the advertisement make clear whether the outcome described is typical. Non-typical results require a clear, prominent disclosure.
"FDA approved" and "FDA cleared" have different meanings. A device cleared through the 510(k) pathway has not received full FDA approval. Using "FDA approved" for a 510(k)-cleared device is considered misleading. The accurate term is "FDA cleared." Full FDA approval applies to devices reviewed through the premarket approval (PMA) pathway.
Yes. Every public-facing social media post that promotes your practice or a specific procedure is subject to FTC advertising standards. Endorsement disclosures must be clear and conspicuous, placed where consumers are likely to see them, not buried in hashtags at the end of a caption.
FTC enforcement can result in civil penalties, cease-and-desist orders, mandatory corrective advertising, and injunctions. FDA violations can result in warning letters, injunctions, consent decrees, and civil money penalties. State Medical Board violations can result in reprimand, conditions on licence, suspension, or revocation. Civil litigation from patients is also a significant risk.
No. The FTC does not pre-approve advertising. It is the advertiser's responsibility to ensure all claims are substantiated before publication.
State Medical Board rules apply alongside, not instead of, FTC and FDA requirements. Compliance with federal standards does not guarantee compliance with state-level rules on titles, scope of practice, or patient solicitation. Practitioners must review the advertising guidance issued by the medical board in each state where they are licensed.
This article is intended for informational purposes only and does not constitute legal advice. Advertising laws and regulatory guidelines vary by state and are subject to change. US plastic surgeons and their marketing teams are encouraged to refer directly to the FTC, FDA, and the relevant State Medical Board for the most current requirements.
ContentClicks builds compliance-first content marketing for healthcare and medical aesthetics practices. Let’s talk.
Plastic surgeons, cosmetic dentists, and aesthetic clinics trust us to get them found. AI-driven content and marketing, built for the way people search today.
